- Home
- SGRP vs VYNE Comparison
SGRP vs VYNE Comparison
Compare SGRP & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SGRP | VYNE |
|---|---|---|
| Founded | 1967 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.7M | 20.0M |
| IPO Year | 1996 | 2017 |
Fundamental Metrics
Financial Performance| Metric | SGRP | VYNE |
|---|---|---|
| Price | $0.78 | $0.60 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 19.2K | ★ 369.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $196,814,000.00 | N/A |
| Revenue This Year | $7.22 | N/A |
| Revenue Next Year | N/A | $16.67 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.73 | $0.29 |
| 52 Week High | $1.60 | $2.57 |
Technical Indicators
Market Signals| Indicator | SGRP | VYNE |
|---|---|---|
| Relative Strength Index (RSI) | 41.95 | 63.76 |
| Support Level | $0.75 | $0.55 |
| Resistance Level | $0.85 | $0.75 |
| Average True Range (ATR) | 0.03 | 0.02 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 43.22 | 98.91 |
Price Performance
Historical ComparisonAbout SGRP SPAR Group Inc.
SPAR Group Inc is a merchandising and brand marketing services company, providing a broad range of sales-enhancing services to retailers across classes of trade and consumer goods manufacturers and distributors. It also provides a range of services to retailers, consumer goods manufacturers and distributors around the globe. The company divides its operations into three reportable regional segments: Americas, which is comprised of United States, Canada, Brazil and Mexico; Asia-Pacific (APAC), which is comprised of Japan, China, and India; and Europe, Middle East and Africa (EMEA), which is comprised of South Africa. It generates maximum revenue from the Americas.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.